{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:06:54Z","timestamp":1784610414954,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grand-in-aid for scientific research","award":["C26462655"],"award-info":[{"award-number":["C26462655"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"DOI":"10.1007\/s10384-026-01399-0","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:52:08Z","timestamp":1784609528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond mild myopia: a pilot randomized trial of 0.01% atropine in school-aged children with myopia \u2264 \u22124.50 D"],"prefix":"10.1007","author":[{"given":"Eizo","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Yaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-3344","authenticated-orcid":false,"given":"Satoshi","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"1399_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine. Ophthalmology. 2019;126:113\u201324.","journal-title":"Ophthalmology"},{"key":"1399_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138:1178\u201384.","journal-title":"JAMA Ophthalmol"},{"key":"1399_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65:315\u201325.","journal-title":"Jpn J Ophthalmol"},{"key":"1399_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, et al. Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology. 2021;128:1367\u20139.","journal-title":"Ophthalmology"},{"key":"1399_CR5","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SS Lee","year":"2022","unstructured":"Lee SS, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multiracial cohort of Australian children: a randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"key":"1399_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365.","journal-title":"JAMA Ophthalmol"},{"key":"1399_CR7","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and safety of 001% and 002% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"1399_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12886-023-03177-9","volume":"23","author":"NC Hansen","year":"2023","unstructured":"Hansen NC, Hvid-Hansen A, M\u00f8ller F, Bek T, Larsen DA, Jacobsen N, et al. One-year efficacy and safety of low-dose atropine (0.01%) eye drops in Danish children with myopia: a randomized placebo-controlled, double-masked trial. BMC Ophthalmol. 2023;23:438.","journal-title":"BMC Ophthalmol"},{"key":"1399_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/APO.0000000000000609","volume":"12","author":"A Chia","year":"2023","unstructured":"Chia A, Ngo C, Choudry N, Yamakawa Y, Tan D. Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study. Asia Pac J Ophthalmol (Phila). 2023;12:370\u20136.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"1399_CR10","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children (MOSAIC): two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102:e245\u20136.","journal-title":"Acta Ophthalmol"},{"key":"1399_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamaophthalmol.2024.2295","volume":"142","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li T, Zuo X, Zhang T, Liu L, Zhou C, et al. 0.01% atropine eye drops in children with myopia and intermittent exotropia: the Amixt randomized clinical trial. JAMA Ophthalmol. 2024;142:722\u201330.","journal-title":"JAMA Ophthalmol"},{"key":"1399_CR12","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.xops.2025.100960","volume":"6","author":"K Ohno-Matsui","year":"2025","unstructured":"Ohno-Matsui K, Igarashi-Yokoi T, Migita Y, Yamakawa Y, ORANGE Study Investigators. Efficacy and safety of low-concentration atropine in slowing myopia progression in children in Japan: the randomized, double-blind Phase 2\/3 ORANGE study. Ophthalmol Sci. 2025;6:100960.","journal-title":"Ophthalmol Sci"},{"key":"1399_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2012.06.004","volume":"31","author":"DI Flitcroft","year":"2012","unstructured":"Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31:622\u201360.","journal-title":"Prog Retin Eye Res"},{"key":"1399_CR14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","volume":"96","author":"MA Bullimore","year":"2019","unstructured":"Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci. 2019;96:463\u20135.","journal-title":"Optom Vis Sci"},{"key":"1399_CR15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA. The risks and benefits of myopia control. Ophthalmology. 2021;128:1640\u20132.","journal-title":"Ophthalmology"},{"key":"1399_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10978-3","volume":"12","author":"LC Lee","year":"2022","unstructured":"Lee LC, Hsieh MW, Chen YH, Chen PL, Chien KH. Characteristics of responders to atropine 0.01% as treatment in Asian myopic children. Sci Rep. 2022;12:7380.","journal-title":"Sci Rep"},{"key":"1399_CR17","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1097\/OPX.0b013e3181940669","volume":"86","author":"NA McBrien","year":"2009","unstructured":"McBrien NA, Jobling AI, Gentle A. Biomechanics of the sclera in myopia: extracellular and cellular factors. Optom Vis Sci. 2009;86:E23-30.","journal-title":"Optom Vis Sci"},{"key":"1399_CR18","first-page":"172","volume":"170","author":"S Backhouse","year":"2018","unstructured":"Backhouse S, Gentle A. Scleral remodelling in myopia and its manipulation. Exp Eye Res. 2018;170:172\u201389.","journal-title":"Exp Eye Res"},{"key":"1399_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.18240\/ijo.2022.03.21","volume":"15","author":"Q Yu","year":"2022","unstructured":"Yu Q, Zhou JB. Scleral remodeling in myopia development. Int J Ophthalmol. 2022;15:510\u20134.","journal-title":"Int J Ophthalmol"},{"key":"1399_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.65.12.21","volume":"65","author":"P Lamirande","year":"2024","unstructured":"Lamirande P, Gaffney EA, Gertz M, Maini PK, Crawshaw JR, Caruso A. A First-Passage model of intravitreal drug delivery and residence time-influence of ocular geometry, Individual variability, and injection location. Invest Ophthalmol Vis Sci. 2024;65:21.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1399_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963\u201374.","journal-title":"Biometrics"},{"key":"1399_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/opo.12009","volume":"33","author":"RA Armstrong","year":"2013","unstructured":"Armstrong RA. Statistical guidelines for the analysis of data obtained from one or both eyes. Ophthalmic Physiol Opt. 2013;33:7\u201314.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1399_CR23","first-page":"32","volume-title":"Design and analysis of cross-over trials","author":"B Jones","year":"2015","unstructured":"Jones B, Kenward MG. Design and analysis of cross-over trials. 3rd ed. Boca Raton: Chapman & Hall\/CRC; 2015. p. 32\u201343.","edition":"3rd ed"},{"key":"1399_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2307\/2533565","volume":"53","author":"SJ Wang","year":"1997","unstructured":"Wang SJ, Hung HM. Use of two-stage test statistic in the two-period crossover trials. Biometrics. 1997;53:1081\u201391.","journal-title":"Biometrics"},{"key":"1399_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1497667","volume":"16","author":"P Navarra","year":"2025","unstructured":"Navarra P, Buzzonetti L, Amico V, Cro M, Federico B. A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children\u2019s populations. Front Pharmacol. 2025;16:1497667.","journal-title":"Front Pharmacol"},{"key":"1399_CR26","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","volume":"128","author":"FF Li","year":"2021","unstructured":"Li FF, Zhang Y, Zhang X, Yip BHK, Tang SM, Kam KW, et al. Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study. Ophthalmology. 2021;128:1180\u20137.","journal-title":"Ophthalmology"},{"key":"1399_CR27","doi-asserted-by":"publisher","first-page":"11588","DOI":"10.1038\/s41598-022-15686-6","volume":"12","author":"HHL Chan","year":"2022","unstructured":"Chan HHL, Choi KY, Ng ALK, Choy BNK, Chan JCH, Chan SSH, et al. Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response. Sci Rep. 2022;12:11588.","journal-title":"Sci Rep"},{"key":"1399_CR28","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.4103\/ijo.IJO_679_22","volume":"70","author":"P Agarwal","year":"2022","unstructured":"Agarwal P, Khurana A, Maan V, Sutar S, Chauhan L. Role of 0.01% atropine in high myopic children of Moradabad, India (RAMCOM study). Indian J Ophthalmol. 2022;70:4400\u20134.","journal-title":"Indian J Ophthalmol"},{"key":"1399_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051506","volume":"13","author":"SH Lee","year":"2024","unstructured":"Lee SH, Tseng BY, Wang JH, Chiu CJ. Efficacy and safety of low-dose atropine on myopia prevention in premyopic children: systematic review and meta-analysis. J Clin Med. 2024;13:1506.","journal-title":"J Clin Med"},{"key":"1399_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254061","volume":"16","author":"LVT Rose","year":"2021","unstructured":"Rose LVT, Schulz AM, Graham SL. Use baseline measurements in myopic patients to predict the control of myopia with and without atropine 0.01. PLoS ONE. 2021;16:e0254061.","journal-title":"PLoS ONE"},{"key":"1399_CR31","doi-asserted-by":"publisher","first-page":"1343698","DOI":"10.3389\/fphar.2024.1343698","volume":"15","author":"SH Lee","year":"2024","unstructured":"Lee SH, Tsai PC, Chiu YC, Wang JH, Chiu CJ. Myopia progression after cessation of atropine in children: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1343698.","journal-title":"Front Pharmacol"},{"key":"1399_CR32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ophtha.2016.04.029","volume":"123","author":"T Yokoi","year":"2016","unstructured":"Yokoi T, Jonas JB, Shimada N, Nagaoka N, Moriyama M, Yoshida T, et al. Peripapillary diffuse chorioretinal atrophy in children as a sign of eventual pathologic myopia in adults. Ophthalmology. 2016;123:1783\u20137.","journal-title":"Ophthalmology"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01399-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:52:10Z","timestamp":1784609530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01399-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":32,"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01399-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E. Tanaka, None; Y. Morizane, None; S. Fujii, None; M. Yaida, None; W. Sun, None; S. Hasebe, None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}